ResMed Inc. (RMD) Shares Bought by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. grew its stake in ResMed Inc. (NYSE:RMD) by 9.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 107,882 shares of the medical equipment provider’s stock after acquiring an additional 8,939 shares during the period. Crossmark Global Holdings Inc. owned 0.08% of ResMed worth $9,137,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Stephens Investment Management Group LLC grew its position in shares of ResMed by 0.3% during the 4th quarter. Stephens Investment Management Group LLC now owns 357,782 shares of the medical equipment provider’s stock worth $30,301,000 after buying an additional 1,068 shares during the period. Calton & Associates Inc. acquired a new position in ResMed during the fourth quarter valued at approximately $115,000. Dowling & Yahnke LLC acquired a new position in ResMed during the fourth quarter valued at approximately $208,000. Public Employees Retirement Association of Colorado grew its holdings in ResMed by 3.4% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 27,251 shares of the medical equipment provider’s stock valued at $2,308,000 after purchasing an additional 889 shares during the period. Finally, Everence Capital Management Inc. acquired a new position in ResMed during the fourth quarter valued at approximately $293,000. 61.47% of the stock is owned by institutional investors.

A number of research analysts recently issued reports on RMD shares. Zacks Investment Research upgraded shares of ResMed from a “hold” rating to a “buy” rating and set a $99.00 price objective for the company in a report on Thursday, January 18th. Needham & Company LLC upgraded shares of ResMed from an “underperform” rating to a “hold” rating in a report on Tuesday, January 23rd. BMO Capital Markets boosted their price objective on shares of ResMed from $70.00 to $74.00 and gave the company a “market perform” rating in a report on Friday, October 27th. Finally, Northland Securities upgraded shares of ResMed from an “under perform” rating to a “market perform” rating in a report on Tuesday, January 23rd. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company. ResMed currently has a consensus rating of “Hold” and an average target price of $76.00.

In other ResMed news, Director Ronald R. Taylor sold 4,885 shares of the company’s stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $99.71, for a total transaction of $487,083.35. Following the sale, the director now directly owns 21,751 shares of the company’s stock, valued at $2,168,792.21. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider James Hollingshead sold 7,019 shares of the company’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $84.16, for a total transaction of $590,719.04. Following the sale, the insider now directly owns 66,409 shares in the company, valued at $5,588,981.44. The disclosure for this sale can be found here. Insiders have sold 49,802 shares of company stock worth $4,824,727 over the last ninety days. Insiders own 1.77% of the company’s stock.

ResMed Inc. (NYSE:RMD) traded up $0.09 during trading on Wednesday, hitting $91.61. 105,228 shares of the stock traded hands, compared to its average volume of 843,185. The firm has a market capitalization of $13,110.70, a PE ratio of 29.21 and a beta of 0.92. ResMed Inc. has a 12 month low of $67.04 and a 12 month high of $104.78.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Monday, January 22nd. The medical equipment provider reported $1.00 EPS for the quarter, topping the Zacks’ consensus estimate of $0.78 by $0.22. The business had revenue of $601.27 million for the quarter, compared to analyst estimates of $583.77 million. ResMed had a net margin of 12.98% and a return on equity of 22.75%. The firm’s revenue for the quarter was up 13.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.73 earnings per share. equities research analysts predict that ResMed Inc. will post 3.34 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 15th. Shareholders of record on Thursday, February 8th will be given a dividend of $0.35 per share. This represents a $1.40 annualized dividend and a yield of 1.53%. The ex-dividend date of this dividend is Wednesday, February 7th. ResMed’s dividend payout ratio (DPR) is currently 70.00%.

WARNING: “ResMed Inc. (RMD) Shares Bought by Crossmark Global Holdings Inc.” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/14/crossmark-global-holdings-inc-purchases-8939-shares-of-resmed-inc-rmd.html.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply